Clik here to view.
Cormark raises QLT price target
On the heels of QLT (NASDAQ:QLTI; TSX:QLT) reaching a 52-week high of $5.45 (U.S.) on Wednesday, Cormark Securities raised its price target to $6.50 from $5.35, maintaining a “buy” rating on the stock....
View ArticleProtected: QLT has positive outcomes treating LCA
This content is password protected. To view it please enter your password below: Password:
View ArticleClik here to view.
QLT hikes size of share buyback
The board of QLT approved an increase in the number of common shares the company (TSX:QLT; NASDAQ:QLTI) may purchase under its normal course issuer bid to 4,700,060, or 10% of the public float, from...
View ArticleClik here to view.
QLT delays AGM to prepare for proxy battle
QLT (NASDAQ:QLTI; TSX:QLT) has delayed its annual meeting to June 4 from today after its second largest shareholder – Nordic Biotech of Denmark – initiated a proxy contest on Wednesday to elect a...
View ArticleClik here to view.
Dissident shareholders overhaul QLT Board
QLT (NASDAQ:QLTI; TSX:QLT) has announced that shareholders elected 6 new directors and 1 carryover from the past board after its second largest shareholder – Nordic Biotech of Denmark – initiated a...
View ArticleClik here to view.
Mati Therapeutics isn’t your traditional biotech startup
Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to...
View ArticleClik here to view.
QLT to merge into Auxilium Pharma
One of Canada’s iconic drug developers, QLT (NASDAQ:QLTI; TSX:QLT), which developed the first treatment for wet age-related macular degeneration, is disappearing through a merger with Auxilium...
View Article
